O site do Hospital Beatriz Ângelo usa cookies para assegurar uma experiência de utilização adequada e para conhecer o fluxo de visitas e suas características.
Ao navegar neste site está a consentir a utilização de cookies. Para mais informações consulte a Política de Cookies.
Serviço Nacional de Saúde
República Portuguesa

Hospital Beatriz Ângelo

Navegação Principal do site

Ensaios clínicos com recrutamento fechado

Ensaios clínicos na área da doença de Alzheimer
  • BI 12897: A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared to donepezil and placebo in patients with cognitive impairment due to Alzheimer's Disease. Mais informações em:

Ensaios clínicos na área da asma
  • TRIGGER: A 52 week, randomized, double blind, multinational, multicentre, active controlled, 3-arm parallel group trial comparing CHF 5993 200/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) to CHF 1535 200/6 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) alone or on top of open-label tiotropium 2.5 µg Respimat® in patients with asthma uncontrolled on high doses of inhaled corticosteroids in combination with long-acting ß2-agonists. Mais informações em:

Ensaios clínicos na área da doença pulmonar obstrutiva
  • TRIBUTE: A 52-week, Double Blind, Double dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group, active Controlled Clinical Trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrronium bromide administered via pMDI (CHF 5993) versus indacaterol/glycopyrronium (Ultibro®) via DPI in patients with Chronic Obstructive Pulmonary Disease. Mais informações em:
Ensaios clínicos na área do acidente vascular cerebral
  • RESPECT ESUS: Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the Efficacy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of Undetermined Source. Mais informações em:
Ensaios clínicos na área do carcinoma da bexiga
  • GO29294:A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of MPDL3280A (anti-PD-L1 antibody) compared with chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer after failure with platinum-containing chemotherapy. Mais informações em:

  • Danube: A Phase III, Randomized, Open-label, Controlled, Multi Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer. Mais informações em:
Ensaios clínicos na área do carcinoma da pulmão
    • GO29438: A phase III, open-label, randomized studyof atezolizumab (mpdl3280a, anti−pd-l1 antibody) in combination with carboplatin or cisplatin+pemetrexe compared with carboplatin or cisplatin+pemetrexed in patients who are chemotherapy-naive and have stage iv non-squamous non−small cell lung cancer. Mais informações em:

    Ensaios clínicos na área do carcinoma mama
    • FB-7: A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer. Mais informações em:

    • GO29505: A phase II randomized, double-blind study of ipatasertib (GDC-0068), an inhibitor to Akt in combination with paclitaxel as neoadjuvant treatment for patients with early stage triple negative breast cancer. Mais informações em:

    • SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment. Mais informações em:
    Ensaios clínicos na área da colite ulcerosa

    Ensaios clínicos na área da esclerose múltipla

    Luz Saúde, S.A., Sociedade Aberta © 2018